Poxel, Sumitomo launch Phase III program of imeglimin in diabebetes

Poxel S.A. (Euronext:POXEL) and Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) began the double-blind, placebo-controlled, 24-week Japanese Phase III

Read the full 186 word article

User Sign In